港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

瑞博生物-B

54.800

-0.050-0.09%

成交量：- -

成交额：- -

市值：93.46亿

市盈率：-26.09

高：54.800

开：54.800

低：54.800

收：54.850

52周最高：95.800

52周最低：51.200

股本：1.71亿

香港流通股本：1.71亿

量比：- -

换手率：- -

股息：- -

股息率：- -

每股收益(LYR):-2.100

净资产收益率：--

总资产收益率：-23.42%

市净率：-87.96

市盈率(LYR):-26.09

市销率: 55.64

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

瑞博生物-B(06938.HK)：建议撤销监事会

瑞博生物-B(06938)拟采纳H股购股权计划及H股激励计划

瑞博生物-B(06938)：Anders Gabrielsen获委任为公司首席医学官

瑞博生物-B(06938)2025年实现收入约1.485亿元，同比增加4.1%

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/06938"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06938","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"瑞博生物-B","latestPrice":54.8,"timestamp":1774575285489,"preClose":54.85,"halted":0,"volume":0,"delay":0,"changeRate":-0.0009115770282589656,"floatShares":170554910,"shares":170554910,"eps":-2.100221,"marketStatus":"交易中","change":-0.05,"latestTime":"03-27 09:35:12","open":54.8,"high":54.8,"low":54.8,"amount":0,"amplitude":0,"askPrice":54.8,"askSize":400,"bidPrice":54.05,"bidSize":9400,"shortable":0,"etf":0,"ttmEps":-1.805,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1774584000000},"marketStatusCode":2,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":54.85,"openAndCloseTimeList":[[1774575000000,1774584000000],[1774587600000,1774598400000]],"volumeRatio":0,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","floatShares":170554910,"roa":"-23.42%","roe":"--","lyrEps":-2.100221,"shares":170554910,"dividePrice":0,"high":54.8,"amplitude":0,"preClose":54.85,"low":54.8,"week52Low":51.2,"pbRate":"-87.96","psRate":"55.64","week52High":95.8,"institutionHeld":0,"latestPrice":54.8,"committee":0.918367,"eps":-2.100221,"divideRate":0,"volume":0,"delay":0,"ttmEps":-1.805,"open":54.8,"prevYearClose":57.97,"prevWeekClose":57.05,"prevMonthClose":68.5,"prevQuarterClose":57.97,"fiveDayClose":57.05,"twentyDayClose":68.5,"sixtyDayClose":57.97},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06938\",params:#limit:5,,,undefined,":[{"date":"2026-03-25","symbol":"06938","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774402200000,"name":null,"time":"","dateTimestamp":1774368000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06938\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06938\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1773417600000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06938\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06938","date":"2026-03-25","current":-34.178753,"percent":0.923077,"low":-50.513246,"twenty":-48.38493,"median":-40.573567,"eighty":-38.714579,"high":-35.975036,"avg":-42.456568,"sd":4.509362,"marketCap":9389047795},"quantilePoints":[{"date":"2026-02-13","current":-47.784644,"twenty":-49.967526,"median":-49.148945,"eighty":-48.330365,"marketCap":11947371445},{"date":"2026-02-20","current":-49.493094,"twenty":-49.901155,"median":-49.02522,"eighty":-48.248265,"marketCap":12356703229},{"date":"2026-02-27","current":-46.28708,"twenty":-49.778496,"median":-48.557346,"eighty":-47.185619,"marketCap":11683011335},{"date":"2026-03-06","current":-41.043234,"twenty":-48.963884,"median":-47.035862,"eighty":-41.420692,"marketCap":10275933327},{"date":"2026-03-13","current":-37.939269,"twenty":-48.578839,"median":-43.677981,"eighty":-39.627323,"marketCap":9542547214},{"date":"2026-03-20","current":-38.832211,"twenty":-48.543939,"median":-40.85279,"eighty":-39.405242,"marketCap":9730157615},{"date":"2026-03-25","current":-37.550977,"twenty":-48.38493,"median":-40.573567,"eighty":-38.714579,"marketCap":9389047795}],"updateTime":1774545734987},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06938\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622687070","title":"瑞博生物-B(06938.HK)：建议撤销监事会","url":"https://stock-news.laohu8.com/highlight/detail?id=2622687070","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622687070?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 23:17","pubTimestamp":1774451824,"startTime":"0","endTime":"0","summary":"格隆汇3月25日丨瑞博生物-B(06938.HK)宣布，为(i)使公司公司章程符合有关举行混合式股东大会、提供电子投票及对香港联合交易所有限公司证券上市规则作出相关修订的最新监管规定；及(ii)根据《中华人民共和国公司法》、中国证券监督管理委员会发布的《上市公司章程指引》及《上市公司股东会规则》以及其他法律法规的最新监管规定(其中规定中国上市公司撤销监事会并进一步完善企业管治)，结合公司实际情况，董事会审议及批准(其中包括)有关修订公司章程、公司股东大会议事规则及董事会议事规则。同时，根据前述法律法规和监管规定，公司拟撤销公司监事会，监事会的相关职权将由董事会审计委员会行使。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260325/32098708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","06938"],"gpt_icon":0},{"id":"2622511077","title":"瑞博生物-B(06938)拟采纳H股购股权计划及H股激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2622511077","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622511077?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 22:50","pubTimestamp":1774450252,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B(06938)发布公告，于2026年3月25日，董事会议决建议采纳本公司H股购股权计划(H股购股权计划)及H股激励计划(H股激励计划，统称为“股份计划”)，惟须待本公司股东批准后，方可作实。股份计划旨在为合资格人士(包括雇员参与者、服务提供者及相关实体参与者)提供获得本公司专有权益的机会，藉以鼓励合资格人士为本公司及股东的整体利益积极工作，提升本公司及本公司股份的价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419099.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06938"],"gpt_icon":0},{"id":"2622072754","title":"瑞博生物-B(06938)：Anders Gabrielsen获委任为公司首席医学官","url":"https://stock-news.laohu8.com/highlight/detail?id=2622072754","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622072754?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 22:38","pubTimestamp":1774449502,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B(06938)发布公告，Anders Gabrielsen博士已获委任为公司首席医学官，将负责公司的整体临床开发、医学事务及监管合规;John Taylor博士已获委任为公司首席商务官，将负责公司的整体商务发展、授权引进及对外许可合作以及战略投资;甘黎明博士不再担任首席医学官，但将继续担任公司的执行董事、联席首席执行官兼全球研发总裁，均自2026年3月25日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419085.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06938"],"gpt_icon":0},{"id":"2622756072","title":"瑞博生物-B(06938)2025年实现收入约1.485亿元，同比增加4.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622756072","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622756072?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 22:35","pubTimestamp":1774449346,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B 公布2025年业绩，收入约1.485亿元，同比增加4.1%。毛利约1.35亿元，同比增加3.3%。研发开支约2.8亿元，基本持平。公告称，收入增长主要是由于勃林格殷格翰合作及兴博润销售核苷单体相关产品所产生的收入增加所致。自成立以来，公司已分别与勃林格殷格翰及齐鲁制药订立多项许可及合作协议，总交易价值超过21亿美元。根据有关协议，公司已授予Madrigal开发、生产及商业化若干siRNA资产的独家全球许可。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06938"],"gpt_icon":0}],"pageSize":4,"totalPage":25,"pageCount":1,"totalSize":98,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/06938\",params:#limit:6,delay:false,,,undefined,":[]}}